On Dec 29, we issued an updated research report on Willis Group Holdings Public Limited Company ( WSH ). In its third quarter, Willis Group missed the Zacks Consensus Estimate and also fell short of the year-ago earnings due to higher expenses. However, the top line improved on higher organic growth in commissions and fees. […]
Leggett & Platt Inc. ( LEG ) has been gaining traction on the back of its long-term strategic initiatives focused on boosting its top line and the policy of streamlining its business portfolio through acquisitions and divestitures. Its strong financial base and sturdy quarterly performances also position it well […]
On Dec 25, 2014, Zacks Investment Research downgraded Sonic Foundry, Inc. ( SOFO ) to a Zacks Rank #5 (Strong Sell). […]
On Dec 30, Zacks Investment Research downgraded MeadWestvaco Corporation ( MWV ) to a Zacks Rank #3 (Hold). Going by the Zacks model, companies holding a Zacks Rank #3 are expected to perform in line with the broader markets. […]
Dunkin' Brands Group, Inc. ( DNKN ) is ready to welcome 2015 with two new items — Chocolate Croissant and Tomato Mozzarella Supreme Bagel. These will be available throughout early 2015 in all participating Dunkin’ restaurants across the U.S. […]
On Dec 30, Zacks Investment Research upgraded StanCorp Financial Group Inc . ( SFG ) to a Zacks Rank #1 (Strong Buy). […]
AMAG Pharmaceuticals, Inc. ( AMAG ) and Takeda Pharmaceutical Company Ltd. ( TKPYY ) announced their decision to mutually terminate their licensing deal for Feraheme in the ex-U.S. […]
Publicly traded energy pipeline partnership, Williams Partners L.P. ( WPZ ) announced that its expanded Geismar plant will begin ethylene sale in Jan 2015. […]
On Dec 27, Zacks Investment Research downgraded energy services holding company AGL Resources Inc. ( GAS ), to a Zacks Rank #4 (Sell). Why the Downgrade […]
Fosun to Acquire Meadowbrook Insurance Group, Inc. Transaction Enables Fosun to Establish Significant Presence in the U.S. […]
BioMarin Pharmaceutical Inc. ( BMRN ) announced that the Japanese Ministry of Health, Labour and Welfare has approved the company’s enzyme replacement therapy, Vimizim, for the treatment of patients suffering from mucopolysaccharidosis type IVA or Morquio A syndrome. Vimizim was reviewed by the Japanese regulatory authority under the orphan drug program. […]
On Dec 30, Zacks Investment Research upgraded Eden Prairie, MN-based CH Robinson Worldwide Inc. ( CHRW ) to a Zacks Rank #2 (Buy). Why the upgrade […]
On Dec 23, 2014, we issued an updated research report on Prosperity Bancshares Inc. ( PB ). Appreciable top-line growth remained the company’s strength, while weak expense management continued to disappoint. […]
On Dec 30, Zacks Investment Research upgraded W.R. Berkley Corporation ( WRB ) to a Zacks Rank #1 (Strong Buy). Why the Upgrade […]
Qualcomm Inc. ( QCOM ), the largest global manufacturer of wireless chipsets, is set to lay off in excess of 100 workers in San Jose and Santa Clara. The retrenchment will represent a small percentage of Qualcomm's 31,300 employees. […]
Repros Therapeutics Inc. ( RPRX ) announced that it has submitted a complete response to the guidance provided by the FDA last month regarding the expected new drug application (NDA) submission for Androxal (read more: Repros Soars on Positive FDA Meeting Regarding Androxa ). Shares of the company gained 6.7% after the announcement […]
Investors in the pharma/biotech sector eagerly wait for pipeline updates as they play an important role in deciding whether or not to invest in a particular company. These updates provide information on experimental drugs and at times give an insight into the commercial potential of the candidate once it is successfully developed and commercialized. Last week, Teva Pharmaceutical Industries Ltd. […]
The issue between The Goldman Sachs Group, Inc. ( GS ) and the Portuguese bank, Banco Espirito Santo over the $835 million debt repayment took a new turn following the Bank of Portugal’s altered stance on the transfer of debt. On Friday, Goldman cautioned that it may contest Bank of Portugal’s decision to not transfer the Banco Espirito debt to Novo Banco – the “good bank” that was created from the split of Banco Espirito in August […]
Athersys, Inc. ( ATHX ) announced the completion of patient enrollment process for a phase II study on its MultiStem cell therapy. The randomized, double-blind, placebo-controlled, multi-center study is evaluating the safety and efficacy of MultiStem therapy in patients suffering from moderate to moderate-severe ischemic strokes […]
Is L Brands, Inc. ( LB ) part of your portfolio? […]
Copyright © 2024 | MH Magazine WordPress Theme by MH Themes